Padhi Somanath, Panda Sandip K
Department of Pathology and Laboratory Medicine,, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India.
Department of Nephrology, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India.
Indian J Nephrol. 2021 Jul-Aug;31(4):331-335. doi: 10.4103/ijn.IJN_229_20. Epub 2021 Apr 2.
Recombinant erythropoietin (rEPO)-associated immunologically driven acquired pure red cell aplasia (PRCA) is an underreported, potentially worsening clinical syndrome in the setting of treatment of anemia of chronic kidney disease. Most cases reported in world literature are related to different formulations of erythropoiesis-stimulating agents with an implication in diagnosis and management. This brief review highlights the clinical guidelines of rEPO usage in nephrology practice, the pathophysiologic mechanism of PRCA, clinical features, diagnosis, and suggested management protocols.
重组促红细胞生成素（rEPO）相关的免疫驱动获得性纯红细胞再生障碍性贫血（PRCA）是慢性肾脏病贫血治疗中一种报道不足、可能会恶化的临床综合征。世界文献中报道的大多数病例与不同剂型的促红细胞生成刺激剂有关，这对诊断和管理有一定影响。本简要综述重点介绍了rEPO在肾脏病学实践中的临床应用指南、PRCA的病理生理机制、临床特征、诊断及建议的管理方案。
